CN Patent

CN109928941A — 一种氢溴酸沃替西汀的结晶化合物及其制备方法

Assigned to CHENGDU HONGDA PHARMACEUTICAL Co Ltd · Expires 2019-06-25 · 7y expired

What this patent protects

本发明涉及氢溴酸沃替西汀结晶化合物及其制备方法。本发明获得的氢溴酸沃替西汀结晶化合物纯度高、溶解性好、吸湿性小，在高温、高湿条件下具有良好的稳定性，且本发的氢溴酸沃替西汀结晶化合物制备方法简单，适合长期储存和工业化生产。

USPTO Abstract

本发明涉及氢溴酸沃替西汀结晶化合物及其制备方法。本发明获得的氢溴酸沃替西汀结晶化合物纯度高、溶解性好、吸湿性小，在高温、高湿条件下具有良好的稳定性，且本发的氢溴酸沃替西汀结晶化合物制备方法简单，适合长期储存和工业化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN109928941A
Jurisdiction
CN
Classification
—
Expires
2019-06-25
Drug substance claim
No
Drug product claim
No
Assignee
CHENGDU HONGDA PHARMACEUTICAL Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.